Four-Gene Signature for Predicting TTK Inhibitor and Taxane Response in Breast Cancer

Supplemental tables from a study identifying a four-gene signature (ETS1, RASSF8, FKBP4, EEF1A2) that predicts sensitivity to the TTK inhibitor CFI-402257 and paclitaxel in breast cancer. The dataset was created by Lei Duan and last updated on April 3, 2026. It is a 203.8 MB XLSX file containing data integrated from the Genomics of Drug Sensitivity in Cancer (GDSC) and the Cancer Cell Line Encyclopedia (CCLE).

Use Cases

• Training predictive models for TTK inhibitor sensitivity based on the four-gene signature (ETS1, RASSF8, FKBP4, EEF1A2).
• Stratifying breast cancer patient outcomes based on gene expression patterns mentioned in the study.
• Investigating the relationship between ERK/AKT signaling pathways and drug resistance as described in the mechanistic findings.
• Analyzing synergy between CFI-402257 and paclitaxel treatments using integrated drug sensitivity and transcriptomic data.

Strengths

• Data is integrated from two large-scale, recognized sources: the Genomics of Drug Sensitivity in Cancer (GDSC) and the Cancer Cell Line Encyclopedia (CCLE).
• The study includes functional validation across cell lines, patient cohorts, and in vivo models, as described.
• Dataset is licensed under CC-BY-4.0, permitting open sharing and adaptation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific modeling tasks.
• Data may reflect bias inherent to the specific cell lines and patient cohorts used in the source studies.

Provenance

Source

Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), with validation data from the study.

Collection Method

Integrated analysis of drug sensitivity and transcriptomic profiles, followed by functional validation.

Time Range

null

Freshness

Last updated 2026-04-03 19:39:27; freshness should be verified.

Geography

null